Forbes, April 10, 2017
Nicholas Malfitano

Links

Read the Full Article

Records from the Philadelphia County Court of Common Pleas reveal more than 3,000 new Risperdal lawsuits were filed in the first three months of 2017, driving up the total number of filings in this mass tort program to more than 5,500.

Complex Litigation Center Director Stanley Thompson said he was “aware” of the filings, and the CLC would “deal with them in due course.” Meanwhile, Jason Itkin of Arnold & Itkin in Houston, a plaintiffs attorney who last year won a $77 million verdict for one of his Risperdal clients in a Philadelphia courtroom, says the clock is now ticking on similar claims.

“Johnson & Johnson caused the increase in filings by cancelling tolling agreements on thousands of cases. Johnson & Johnson knew that its strategy would increase the number of cases filed and the burden on the Court,” Itkin said.

Itkin explained the tolling agreements essentially paused the statute of limitations deadline within which a lawsuit needed to be filed and said the company's actions indicated it wanted more litigation in Pennsylvania and not less. [...]

health law policy medical safety mental health pediatrics pharmaceuticals public health regulation